681 related articles for article (PubMed ID: 16869719)
21. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial.
; Forbes JF; Cuzick J; Buzdar A; Howell A; Tobias JS; Baum M
Lancet Oncol; 2008 Jan; 9(1):45-53. PubMed ID: 18083636
[TBL] [Abstract][Full Text] [Related]
22. Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer.
Lester JE; Dodwell D; Purohit OP; Gutcher SA; Ellis SP; Thorpe R; Horsman JM; Brown JE; Hannon RA; Coleman RE
Clin Cancer Res; 2008 Oct; 14(19):6336-42. PubMed ID: 18829518
[TBL] [Abstract][Full Text] [Related]
23. Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial.
Fallowfield L; Cella D; Cuzick J; Francis S; Locker G; Howell A
J Clin Oncol; 2004 Nov; 22(21):4261-71. PubMed ID: 15514369
[TBL] [Abstract][Full Text] [Related]
24. Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal women.
Goss PE; Hadji P; Subar M; Abreu P; Thomsen T; Banke-Bochita J
Breast Cancer Res; 2007; 9(4):R52. PubMed ID: 17692126
[TBL] [Abstract][Full Text] [Related]
25. Adverse events and bone health during anastrozole therapy in postmenopausal Japanese breast cancer patients.
Sagara Y; Kosha S; Baba S; Dokiya F; Tamada S; Sagara Y; Matsuyama Y; Ohi Y; Ando M; Rai Y; Sagara Y; Douchi T
Breast Cancer; 2010 Jul; 17(3):212-7. PubMed ID: 19526308
[TBL] [Abstract][Full Text] [Related]
26. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial.
Jakesz R; Jonat W; Gnant M; Mittlboeck M; Greil R; Tausch C; Hilfrich J; Kwasny W; Menzel C; Samonigg H; Seifert M; Gademann G; Kaufmann M; Wolfgang J;
Lancet; 2005 Aug 6-12; 366(9484):455-62. PubMed ID: 16084253
[TBL] [Abstract][Full Text] [Related]
27. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial.
Boccardo F; Rubagotti A; Puntoni M; Guglielmini P; Amoroso D; Fini A; Paladini G; Mesiti M; Romeo D; Rinaldini M; Scali S; Porpiglia M; Benedetto C; Restuccia N; Buzzi F; Franchi R; Massidda B; Distante V; Amadori D; Sismondi P
J Clin Oncol; 2005 Aug; 23(22):5138-47. PubMed ID: 16009955
[TBL] [Abstract][Full Text] [Related]
28. 'Arimidex' (anastrozole) versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer--efficacy overview.
Buzdar AU;
J Steroid Biochem Mol Biol; 2003 Sep; 86(3-5):399-403. PubMed ID: 14623537
[TBL] [Abstract][Full Text] [Related]
29. Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a.
Jakesz R; Greil R; Gnant M; Schmid M; Kwasny W; Kubista E; Mlineritsch B; Tausch C; Stierer M; Hofbauer F; Renner K; Dadak C; Rücklinger E; Samonigg H;
J Natl Cancer Inst; 2007 Dec; 99(24):1845-53. PubMed ID: 18073378
[TBL] [Abstract][Full Text] [Related]
30. Three years' follow-up from the ATAC trial is sufficient to change clinical practice: a debate.
Aapro MS; Forbes JF
Breast Cancer Res Treat; 2003; 80 Suppl 1():S3-11; discussion S13-8. PubMed ID: 14535530
[TBL] [Abstract][Full Text] [Related]
31. Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results.
Bundred NJ; Campbell ID; Davidson N; DeBoer RH; Eidtmann H; Monnier A; Neven P; von Minckwitz G; Miller JC; Schenk NL; Coleman RE
Cancer; 2008 Mar; 112(5):1001-10. PubMed ID: 18205185
[TBL] [Abstract][Full Text] [Related]
32. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
Jahanzeb M
Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
[TBL] [Abstract][Full Text] [Related]
33. Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer.
Hillner BE
Cancer; 2004 Sep; 101(6):1311-22. PubMed ID: 15368322
[TBL] [Abstract][Full Text] [Related]
34. Bone safety of aromatase inhibitors versus tamoxifen.
Lønning PE
Int J Gynecol Cancer; 2006; 16 Suppl 2():518-20. PubMed ID: 17010062
[TBL] [Abstract][Full Text] [Related]
35. The ATAC adjuvant breast-cancer trial: six-year results of the endometrial subprotocol.
Duffy S; Jackson TL; Lansdown M; Philips K; Wells M; Clack G; Bianco AR;
J Obstet Gynaecol; 2010; 30(6):596-604. PubMed ID: 20701510
[TBL] [Abstract][Full Text] [Related]
36. Anastrozole is cost-effective vs tamoxifen as initial adjuvant therapy in early breast cancer: Canadian perspectives on the ATAC completed-treatment analysis.
Rocchi A; Verma S
Support Care Cancer; 2006 Sep; 14(9):917-27. PubMed ID: 16596419
[TBL] [Abstract][Full Text] [Related]
37. Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis.
Sestak I; Cuzick J; Sapunar F; Eastell R; Forbes JF; Bianco AR; Buzdar AU;
Lancet Oncol; 2008 Sep; 9(9):866-72. PubMed ID: 18703382
[TBL] [Abstract][Full Text] [Related]
38. Is long-term adjuvant treatment of breast cancer with anastrozole indicated?
Doggrell SA
Expert Opin Pharmacother; 2008 Jun; 9(9):1619-22. PubMed ID: 18518790
[TBL] [Abstract][Full Text] [Related]
39. The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: first results of the endometrial sub-protocol following 2 years of treatment.
Duffy S; Jackson TL; Lansdown M; Philips K; Wells M; Pollard S; Clack G; Coibion M; Bianco AR
Hum Reprod; 2006 Feb; 21(2):545-53. PubMed ID: 16210385
[TBL] [Abstract][Full Text] [Related]
40. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial.
Smith IE; Dowsett M; Ebbs SR; Dixon JM; Skene A; Blohmer JU; Ashley SE; Francis S; Boeddinghaus I; Walsh G;
J Clin Oncol; 2005 Aug; 23(22):5108-16. PubMed ID: 15998903
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
